Omega-3 Fatty Acids for Major Depressive Disorder During Pregnancy
Not Applicable
Completed
- Conditions
- Depressive Disorder
- Interventions
- Dietary Supplement: Omega-3 fatty acids
- Registration Number
- NCT00618865
- Lead Sponsor
- National Science Council, Taiwan
- Brief Summary
Whether high-dose omega-3 fatty acids supplement would be an effective treatment in patients with major depressive disorder during pregnancy and breast-feeding.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 36
Inclusion Criteria
- Eligible participants were pregnant women, aged 18 to 40 years, with major depressive disorder onset between their 16th week (second trimester) and 32nd week (third trimester) of gestation at the Department of Obstetrics.
Exclusion Criteria
- Subjects were excluded with a DSM-IV diagnosis of bipolar disorders, psychotic disorders, substance abuse or dependence for at least 3 months, or any Axis-II diagnosis of borderline or antisocial personality disorder.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Omega-3 fatty acids omega-3 fatty acid with 2.2 g of eicosapentanoic acid (EPA) and 1.2 g of docosahexanoic acid (DHA) 2 Omega-3 fatty acids Placebo (olive oil ethyl esters)
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method